Global Locations

Sodium valproate

ISO 17034:
Catalog Number : CS-O-02302
CAS Number : 1069-66-5
Status : Available for immediate dispatch
Sodium valproate is a Controlled Substance.
For exact pricing and delivery please contact sales@clearsynth.com

Custom Quote

Send us a request for Custom
pack size and pricing.

Synthesis Advice

Schedule a call with our Experts to
answer your questions.

Instant Help

Connect with our Live Chat
representatives for instant help.

Chemical Information

Chemical Name : Sodium valproate
Category : API Standards
Purity : Not less than 95 %
Synonyms : Not available
Molecular Weight : 166.19 mol/g
Molecular Formula : C₈H₁₅NaO₂
Application : "Valproate Sodium is the sodium salt form of valproic acid with anti-epileptic activity. Valproate sodium is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, valproate sodium increases conc"

Shipping & Availability

Status: : Available for immediate dispatch
COA :
[Login Needed]
MSDS :
[Login Needed]
Hazardous Compound : No
Controlled Substance : Yes

Purchase Options

Payment mode : Credit / Debit / Purchase Order
Taxes : All prices are inclusive taxes
Refund Policy : 30 days money back guarantee

Additional Information

Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

Common side effects of valproate include nausea, vomiting, sleepiness, and dry mouth. Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. Other serious risks include pancreatitis and an increased suicide risk. Valproate is known to cause serious abnormalities in babies if taken during pregnancy, and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition. As of 2022 the drug was still prescribed in the UK to potentially pregnant women, but use declined by 51% from 2018\u201319 to 2020\u201321.

Valproate's precise mechanism of action is unclear. Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, and inhibiting histone deacetylases. Valproic acid is a branched short-chain fatty acid (SCFA) made from valeric acid.

Valproate was first made in 1881 and came into medical use in 1962. It is on the World Health Organization's List of Essential Medicines and is available as a generic medication. In 2019, it was the 114th most commonly prescribed medication in the United States, with more than 5\u00a0million prescriptions.


References : "Chang; Z,L,; et al,: Anal, Profiles Drug Subs,; 8; 529 (1979); Della Pachoa; O,E,; et al,: Br, J, Pharmcol,; 125; 1610 (1998); Grimes;c,A,; et al,: J, Neirchem,; 73; 1384 (1999); Locher; W,; Prog, Neurobiol,; 58; 31 (1999);"
Canonical SMILES : CCCC(CCC)C(=O)[O-].[Na+]
Isomeric SMILES : CCCC(CCC)C(=O)[O-].[Na+]
InChI : InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
InchIKey : AEQFSUDEHCCHBT-UHFFFAOYSA-M
IUPAC Name : sodium;2-propylpentanoate
Exact Mass : 166.09697400
Use Classification : Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Hazard Class : Acute Tox. 4 (100%)
Description : Sodium valproate is the sodium salt of valproic acid. It has a role as a geroprotector. It contains a valproate.
EC Number : 213-961-8

Related compounds of Sodium valproate

CAT NO. COMPOUND CAS NO. CATEGORY
CS-T-46266 Valproic acid 99-66-1 API Standards